Phase 2 Seliciclib for Cushing Disease
This study is testing an oral medication called Seliciclib (R-roscovitine) for people with Cushing disease. This condition happens when your body makes too much of a hormone called cortisol. You might be able to join if you are at least 18 years old and have Cushing disease that is newly diagnosed, persistent, or has come back. To qualify, your doctors need to confirm that your Cushing disease is caused by a problem with your pituitary gland. The study will look at whether Seliciclib can lower the amount of cortisol in your body, specifically if your cortisol levels return to normal or are reduced by at least 50% after 4 weeks. Up to 13 people will participate in this study. The current status of this study is unclear.
- Study design
- This is a Phase 2, multicenter, open-label study, meaning both you and your doctors will know you are receiving Seliciclib. Up to 13 participants will be involved.
- What's involved
- You would take 80 mg of Seliciclib by mouth each day for 4 weeks. The study will also assess your quality of life and symptoms of Cushing disease.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcomes are measured at 4 weeks, which is the study completion time.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT03774446
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
Recruiting
PHASE2Ages 18+InterventionalTreatmentCedars-Sinai Medical CenterInvestigator-initiated
~13 participants
Updated 2025-09-11 on ClinicalTrials.gov
What's tested:Seliciclib
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants with a normalized 24-hour urinary free cortisol (UFC) at study completion
Measured over 4 weeks
+1 more outcome measured
Conditions
NCT03774446
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Cedars-Sinai Medical Center
Los Angeles, Californiastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Shlomo Melmed, MD · PRINCIPAL_INVESTIGATOR · Cedars-Sinai Medical Center
- Ning-Ai Liu, MD, PhD · STUDY_DIRECTOR · Cedars-Sinai Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Male and female patients at least 18 years old
Patients with confirmed pituitary origin of excess adrenocorticotropic hormone (ACTH) production:
Persistent hypercortisolemia established by two consecutive 24-hour UFC assessment ≥1.5× the upper limit of normal
Normal or elevated ACTH levels
Pituitary adenoma (\>1 cm) on MRI or inferior petrosal sinus sampling (IPSS) central to peripheral ACTH gradient \>2 at baseline and \>3 after CRH stimulation
Recurrent or persistent CD defined as pathologically confirmed resected pituitary ACTH-secreting tumor or IPSS central to peripheral ACTH gradient \>2 at baseline and \>3 after CRH stimulation, and 24h-UFC \>ULN beyond post-surgical week 6
Patients on medical treatment for Cushing disease. The following washout periods must be completed before screening assessments are performed:
Inhibitors of steroidogenesis: metyrapone, ketoconazole: 2 weeks; Levoketoconazole: 3 weeks; osilodrostat: 6 weeks
Somatostatin receptor ligand pasireotide: short-acting, 2 weeks; long-acting, 4 weeks
Progesterone receptor antagonist mifepristone: 2 weeks
Dopamine agonist cabergoline: 4 weeks
Patients treated with CYP3A or CYP2B6 strong inducers or inhibitors, including those listed below. Required washout time varies between drugs; minimum 5-6 times the half-life of the drug.
Strong CYP3A inducers: apalutamide, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John's wort
Moderate CYP3A inducers: bosentan, efavirenz, etravirine, phenobarbital, primidone
Weak CYP3A inducers: armodafinil, modafinil, rufinamide
Strong CYP2B6 inducer: carbamazepine
Moderate CYP2B6 inducers: efavirenz, rifampin
Weak CYP2B6 inducers: nevirapine, ritonavir
Strong CYP3A inhibitors: boceprevir, cobicistat, danoprevir and ritonavir, elvitegravir and ritonavir, grapefruit juice, indinavir and ritonavir, itraconazole, ketoconazole, lopinavir and ritonavir, paritaprevir and ritonavir and (ombitasvir and/or dasabuvir), posaconazole, ritonavir, saquinavir and ritonavir, telaprevir, tipranavir and ritonavir, telithromycin, troleandomycin, voriconazole, clarithromycin, idelalisib, nefazodone, nelfinavir.
Moderate CYP3A inhibitors: aprepitant, ciprofloxacin, conivaptan, crizotinib, cyclosporine, diltiazem, dronedarone, erythromycin, fluconazole, fluvoxamine, imatinib, verapamil
Strong CYP2B6 inhibitor: ticlopidine
Exclusion
Patients with compromised visual fields, and not stable for at least 6 months
Patients with abutment or compression of the optic chiasm on MRI and normal visual fields
Patients with Cushing's syndrome due to non-pituitary ACTH secretion
Patients with hypercortisolism secondary to adrenal tumors or nodular (primary) bilateral adrenal hyperplasia
Patients who have a known inherited syndrome as the cause for hormone over secretion (i.e., Carney Complex, McCune-Albright syndrome, Multiple endocrine neoplasia (MEN) 1
Patients with a diagnosis of glucocorticoid-remedial aldosteronism (GRA)
Patients with cyclic Cushing's syndrome defined by any measurement of UFC over the previous 1 months within normal range
Patients with pseudo-Cushing's syndrome, i.e., non-autonomous hypercortisolism due to overactivation of the hypothalamic-pituitary-adrenal (HPA) axis in uncontrolled depression, anxiety, obsessive compulsive disorder, morbid obesity, alcoholism, and uncontrolled diabetes mellitus
Patients who have undergone major surgery within 1 month prior to screening
Patients with serum K+\< 3.5 while on replacement treatment
Diabetic patients whose blood glucose is poorly controlled as evidenced by HbA1C \>8%
Patients who have clinically significant impairment in cardiovascular function or are at risk thereof, as evidenced by congestive heart failure (NYHA Class III or IV), unstable angina, sustained ventricular tachycardia, clinically significant bradycardia, high grade atrioventricular (AV) block, history of acute MI less than one year prior to study entry
Patients with liver disease or history of liver disease such as cirrhosis, chronic active hepatitis B and C, or chronic persistent hepatitis, or patients with abnormal alanine transferase (ALT) or aspartate aminotransferase (AST) at screening or patients with advanced liver fibrosis (≥10 kPa) on elastography at screening
Patients with estimated glomerular filtration rate (eGFR) \<45 mL/min/1.73 m2
Patients not biochemically euthyroid
Patients who have any current or prior medical condition that can interfere with the conduct of the study or the evaluation of its results, such as
History of immunocompromise, including a positive HIV test result (ELISA and Western blot). An HIV test will not be required, however, previous medical history will be reviewed
Presence of active or suspected acute or chronic uncontrolled infection
History of, or current alcohol misuse/abuse in the 12 month period prior to screening
Female patients who are pregnant or lactating, or are of childbearing potential and not practicing a medically acceptable method of birth control. If a woman is participating in the trial then one form of contraception is sufficient (pill or diaphragm) and the partner should use a condom. If oral contraception is used in addition to condoms, the patient must have been practicing this method for at least two months prior to screening and must agree to continue the oral contraceptive throughout the course of the study and for 3 months after the study has ended. Male patients who are sexually active are required to use condoms during the study and for three months afterwards as a precautionary measure (available data do not suggest any increased reproductive risk with the study drugs)
Patients who have participated in any clinical investigation with an investigational drug within 1 month prior to screening or patients who have previously been treated with seliciclib
Patients with any ongoing or likely to require additional concomitant medical treatment to treat CD
Patients who have received pituitary irradiation within the last 5 years prior to the baseline visit
Patients who have been treated with radionuclide at any time prior to study entry
Patients with known hypersensitivity to seliciclib
Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable or will be unable to complete the entire study
Patients with hepatitis B surface antigen (HbsAg) positivity
Patients with hepatitis C antibody (anti-HCV) positivity
Patients with prolonged QTcF on screening electrocardiogram (QTcF \>450 msec)
What this trial measures
- Number of participants with a normalized 24-hour urinary free cortisol (UFC) at study completion4 weeks
- Number of participants with UFC above the upper limit of normal (ULN) but reduced by ≥50% from baseline at study completion4 weeks